CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · Science & Nature

Neboglamine

chemical compound

Specimen drawers, botanical folios and brass scientific instruments under study light
Science and natureInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionSep 14, 2026
Entity authorityQ20707894 ↗
Source-derived summary

Neboglamine (INNTooltip International Nonproprietary Name) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence. It shows cognition- and memory-enhancing effects in animal models. As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.

Editorial summary

“Neboglamine” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Neboglamine, chemical and compound can confirm, complicate or overturn.

Editorial reviewA practical orientation to terminology and classification, particularly when read beside dated observations, specimens or technical literature. The current lead gives the account dated anchors—2015—that can be checked directly. The selected authority fields contribute no independent date. Its strongest next move is a source search built around Neboglamine, chemical and compound.
Editorial analysis

Why this record matters

“Neboglamine” is worth following because a concise public description often conceals a longer documentary argument. Here, Neboglamine, chemical and compound provides the most credible route into that argument.

Evidence profile

Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Sep 14, 2026. The linked authority identifier is Q20707894. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2015.

Critical limits

Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.

Best used for
  • Current terminology
  • Classification context
  • Finding cited technical literature
Verify next

Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.

Three-step research path

  1. Establish the record: confirm the title “Neboglamine”, its source revision and the description used here.
  2. Expand the search: follow Neboglamine primary sources, Neboglamine archive and Neboglamine research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Neboglamine”?
  2. Which observation, specimen, dataset or publication supports the account?
  3. Has classification or technical consensus changed since the cited source?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Neboglamine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.